Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes (News-Medical-Net)

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments …
(read here…)

Related items

• Clinical data on CXA-101 to be presented at ICAAC (News-Medical-Net)
• Biomoda applauds Senator for introducing legislative bill for lung cancer screening (News-Medical-Net)
• World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center (News-Medical-Net)
• OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries (News-Medical-Net)
• Rexahn, TheraTarget form nano science research collaboration (PharmaBiz)

Tags: cancer, diabetes, diabetes research foundation, Inc, juvenile diabetes research, juvenile diabetes research foundation, milestone, milestone payment, nano, nanotech, nanotechnology, Osiris, osiris therapeutics inc, Technology, Therapeutics

This entry was posted on Wednesday, January 27th, 2010 at 8:07 pm and is filed under Technology.